Us Bancorp \De\ Coherus Bio Sciences, Inc. Transaction History
Us Bancorp \De\
- $75.6 Billion
- Q4 2024
A detailed history of Us Bancorp \De\ transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 3,001 shares of CHRS stock, worth $2,850. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,001
Previous 3,001
-0.0%
Holding current value
$2,850
Previous $3,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CHRS
# of Institutions
130Shares Held
67.8MCall Options Held
1.68MPut Options Held
91.8K-
Black Rock Inc. New York, NY11.8MShares$11.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$10.6 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.28MShares$5.02 Million0.02% of portfolio
-
Rubric Capital Management LP New York, NY5.26MShares$5 Million0.12% of portfolio
-
Tang Capital Management LLC San Diego, CA3.65MShares$3.47 Million0.38% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $73.8M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...